efpeglenatide (HM11260C) / Hanmi, Sanofi  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
efpeglenatide (HM11260C) / Hanmi
NCT02059564: A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Unknown status
1b
44
US
HM11260C, LAPS-Exendin-4, Placebo, Normal saline solution, Victoza, Liraglutide
Hanmi Pharmaceutical Company Limited
Diabetes Mellitus
10/14
12/14
NCT01093729: A Study of HM11260C in Healthy Male Subject

Completed
1
41
RoW
HM11260C
Hanmi Pharmaceutical Company Limited
Healthy
10/10
10/10

Download Options